Oncology Trials

Research and Education > TriHealth Hatton Research Institute
oncology trials

The TriHealth Hatton Research Institute's Oncology research team, and researchers at  TriHealth’s Cancer Institute and Mary Jo Cropper Family Center for Breast Care conduct important clinical trials targeting improvements in the prevention and treatment of specific kinds of cancer. Composed of a team of research nurses and clinical research assistants, the TriHealth Hatton Research Institute's Oncology research team has many decades of experience in oncology research.

Clinical trials supported by our Oncology research team include cooperative group trials sponsored by the National Cancer Institute, studies through the Catholic Health Initiative, and Pharmaceutical Trials. 

Selected trials:

What is a Clinical Trial?

A clinical trial (also called “clinical research,” “research study,” and “protocol”) is a research study that evaluates a new test, drug or treatment in people to make sure it is safe and effective. Carefully conducted clinical trials are vital to discovering new, better, safer treatments for people, and improve health and quality of life.

Clinical trials are important today for many reasons, including:

  • Contributing to improved scientific knowledge about cancer: how to detect it, and how to treat it, and even how to prevent it
  • Possibly benefiting individual patients by providing newer and better treatments, and possibly, a cure 

More Information

For additional basic information about clinical trials:

Clinical Oncology Trials

Oncology: Molecular Profiling

EAY131: Molecular Analysis for Therapy Choice (MATCH)
Learn more.

Principal Investigator and Contact information:
Andrew Parchman, MD
513 451 4033

Study Coordinator and Contact information:
Deborah Standafer, BSN
513 862 2293
Deborah_standafer@trihealth.com

Oncology: Breast

Alliance A011106:: ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: A Phase III Study. Learn more.

Principal Investigator and Contact information: 
Ching Ho, MD
513 865 1344

Study Coordinator and Contact information: 
Pamela Daniel, RN
513 865 5228
Pam_daniel@trihealth.com

ALLIANCE 011202: A Randomized  Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (CT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy. Learn more.

Principal Investigator and Contact information: 
Ching Ho, MD
513 865 1344

Study Coordinator and Contact information: 
Pamela Daniel, RN
513 865 5228
Pam_daniel@trihealth.com

ALLIANCE A11203: A Randomized Phase II Trial of Tamoxifen versus Z-Endoxifen in Postmenopausal Women with Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer.
Learn more.

Principal Investigator and Contact information: 
Apruva Mehta, MD
513 451 4033 

Study Coordinator and Contact information:  
Nancy Firsich, RN
513 865 5569
Nancy_Firsich@trihealth.com  

ALLIANCE 221102: Randomized Double-Blind Placebo Controlled Study of Subcutaneous Testosterone in the Adjuvant Treatment of Postmenopausal Women with Aromatase Inhibitor Induced Arthralgias. Learn more.

Principal Investigator and Contact information: 
Ching Ho, MD
513 865 1344

Study Coordinator and Contact information: 
Pamela Daniel, RN
513 865 5228
Pam_daniel@trihealth.com  

EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemo-therapy vs. Observation in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy. Learn more.

Principal Investigator and Contact information:
Ching Ho, MD
513 865 1344

Study Coordinator and Contact information:
Pamela Daniel, RN
513 865 5228
Pam_daniel@trihealth.com

ECOG 2112:  A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Men and Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer. Learn more

Principal Investigator and Contact information:  
Apurva Mehta, MD
513 451 4033

Study Coordinator and Contact information:  
Pamela Daniel, RN
513 865 5228
Pam_daniel@trihealth.com  

NRG BR003:A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed By Weekly Paclitaxel With Or Without Carboplatin For Node-Positive Or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer. Learn more.

Principal Investigator and Contact information:
Apurva Mehta, MD
513 451 4033

Study Coordinator and Contact information:
Pamela Daniel, RN
513 865 5228
Pam_daniel@trihealth.com  

NSABP B51/RTOG 1304:  A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy.  Learn more.

Principal Investigator and Contact information: 
Ching Ho, MD
513 865 1344

Study Coordinator and Contact information: 
Pamela Daniel, RN
513 865 5228
Pam_daniel@trihealth.com

NSMR:  Nipple Sparing Mastectomy Registry. Learn more.

Principal Investigator and Contact information:
Ching Ho, MD
513 865 1344

Study Coordinator and Contact information:
Nancy Firsich, RN
513 865 5569
Nancy_firsich@trihealth.com

SWOG 1207: S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer (e3). Learn more.

Principal Investigator and Contact information;
Ching Ho, MD
513 865 1344

Study Coordinator and Contact information:
Pamela Daniel, RN
513 865 5228
Pam_daniel@trihealth.com  

Oncology: Gastrointestinal

ECOG 7208:A Randomized Phase II Study of Irinotecan and Cetuximab with or without the Anti-Angiogenic Antibody, Ramucirumab, in Advanced, K-ras Wild-type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy. Learn more.

Principal Investigator and Contact information:  
David Draper, MD
513 451 4033

Study Coordinator and Contact information:  
Anne Dean, RN
513 862 6915
Antoinette_Dean@trihealth.com

JAVELIN Gastric 100:A Phase III Open-label, Multicenter Trial of Maintenance Therapy with Avelumab (MSB0010718C) versus Continuation of First-Line Chemotherapy in Subjects with Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro-Esophageal Junction. Learn more.

Principal Investigator and Contact information:  
David Draper, MD
513 451 4033

Study Coordinator and Contact information:  
Kate Bieniek, RN
513 862 1650
Kathleen_Bieniek@trihealth.com

JVD PASS (Lilly): Safety and Effectiveness of Ramucirumab in Patients with Advanced Gastric Cancer in the European Union and North America: A Prospective Observational Registry (I4T-MC-JVDD).

Principal Investigator and Contact information:
David Draper, MD
513 451 4033

Study Coordinator and Contact information:
Kate Bieniek, RN
513 862 1650
Kathleen_Bieniek@trihealth.com

RTOG 0848: A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma. Learn more.

Principal Investigator and Contact information:
David Draper, MD
513 451 4033

Study Coordinator and Contact information:
Kate Bieniek, RN
513 862 1650
Kathleen_Bieniek@trihealth.com

Oncology: Gastrointestinal, Preventative

OCCPI: Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome. Learn more.

Principal Investigator and Contact information: 
David Draper, MD
513 451 4033

Study Coordinator and Contact information: 

Anne Dean, RN
513 862 6915
Antoinette_dean@trihealth.com  

Kate Bieniek, RN
513 862 1650
Kathleen_bieniek@trihealth.com  

 

Oncology: Gynecology

GOG 0213: A Phase III RCT of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. Learn more.

Principal Investigator and Contact information:
James Pavelka, MD
513 862 1888

Study Coordinator and Contact information:
Diann Fischesser RN
513 862 1892
Diann_fischesser@trihealth.com

GOG 0225: Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival? Learn more.

Principal Investigator and Contact information:
James Pavelka, MD
513 862 1888

Study Coordinator and Contact information: 
Diann Fischesser RN
513 862 1892
Diann_fischesser@trihealth.com  

GOG 0238: A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus. Learn more.

Principal Investigator and Contact information: 
James Pavelka MD
513 862 1888

Study Coordinator and Contact information: 
Diann Fischesser RN
513 862 1892
Diann_fischesser@trihealth.com

GOG 0286B: A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer. Learn more.

Principal Investigator and Contact information: 
Kevin Schuler, MD
513 862 1888

Study Coordinator and Contact information: 
Diann Fischesser, RN
513 862 1892
Diann_fischesser@trihealth.com

NRG GY003: Phase II Randomized Trial of Nivolumab with or without Ipilimumab in Patients with Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer. Learn more.

Principal Investigator and Contact information: 
James Pavelka,MD
513 862 1888

Study Coordinator and Contact information: 
Diann Fischesser, RN
513 862 1892
Diann_fischesser@trihealth.com

NRG GY004: A Phase III Study Comparing Single-agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-based Chemotherapy in Women with Recurrent Platinum-sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Learn more.

Principal Investigator and Contact information:
James Pavelka,MD
513 862 1888

Study Coordinator and Contact information:
Diann Fischesser, RN
513 862 1892
Diann_fischesser@trihealth.com

NRG GY005:A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS). Learn more.

Principal Investigator and Contact information:
James Pavelka MD
513 862 1888

Study Coordinator and Contact information:
Diann Fischesser RN
513 862 1892
Diann_fischesser@trihealth.com

LCCC 1326: Metformin with the Levonorgestrel-Releasing Intrauterine Device for the treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients. Learn more.

Principal Investigator and Contact information:
Kevin Schuler, MD
513 862 1888

Study Coordinator and Contact information:
Diann Fischesser, RN
513 862 1892
Diann_fischesser@trihealth.com

Oncology: Lung Cancer

A151216: A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST): A screening trial for A081105 and E4512. Learn more.

Principal Investigator and Contact information: 
Andrew Parchman, MD
513 451 4033

Study Coordinator and Contact information: 
Kate Bieniek, RN
513 862 1650
Kathleen_bieniek@trihealth.com

A081105:  A081105: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo In Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC). An ALCHEMIST Treatment Trial. Learn more.

Principal Investigator and Contact information: 
Andrew Parchman, MD
513 451 4033

Study Coordinator and Contact information: 
Kate Bieniek, RN
513 862 1650
Kathleen_bieniek@trihealth.com

ECOG 4512: Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations. An ALCHEMIST Treatment Trial. Learn more.

Principal Investigator and Contact information: 
Andrew Parchman, MD
513 451 4033

Study Coordinator and Contact information: 
Kate Bieniek, RN
513 862 1650
Kathleen_bieniek@trihealth.com

Oncology: Hematologic

CONNECT®: An MDS/AML Disease Registry.  Learn more.

Principal Investigator and Contact information:  
Ranga Brahmamdam, MD
513 451 4033

Study Coordinator and Contact information:  
Anne Dean, RN
513 862 6915
antoinette_dean@trihealth.com

ECOG 1412:  Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma. Learn more.

Principal Investigator and Contact information:  
Ranga Brahmamdam, MD
513 451 4033

Study Coordinator and Contact information:  
Deborah Standafer
513 862 2293
deborah_standafer@trihealth.com

We are physicians, hospitals and communities working together to help you live better.